AMED Amedeo Res

RNS No 3975v
CHIROSCIENCE GROUP PLC
29 April 1999
  
                                       
               CHIROSCIENCE R&D ANNOUNCES KEY MILESTONE IN PDE4
                      COLLABORATION WITH SCHERING-PLOUGH
  
  Chiroscience R&D is pleased to announce that it has achieved a key milestone
  in its PDE4 collaboration with Schering-Plough.
  
  In  June 1997 Chiroscience and Schering-Plough Research Institute signed  an
  agreement to develop selective PDE4 inhibitors as oral treatments for asthma
  and  other inflammatory diseases. The collaboration was designed to  develop
  well-tolerated oral PDE4 inhibitors that can provide symptomatic  relief  by
  preventing  or  reversing  the  development  of  airway  hyperactivity   and
  inflammation.
  
  Under  the  terms  of the agreement, Schering-Plough will make  a  milestone
  payment  to  Chiroscience  which relates to one  of  these  PDE4  inhibitors
  (D4396).  This  compound  has already completed  a  number  of  pre-clinical
  studies,  and  on  successful  completion  of  the  pre-clinical  phase,  is
  projected to enter clinical trials next year.
  
  Schering-Plough  has  worldwide  rights  to  products  developed  from  this
  collaboration  and  has access to all of Chiroscience's PDE4  inhibitors  in
  these  fields. In return Chiroscience received an up-front payment  in  1997
  together with research and development funding.  This funding is expected to
  continue  throughout  1999  as  the  two  companies  extend  their  research
  objectives. Further payments will be made if key development milestones  are
  reached  and  Chiroscience will receive royalties on any  resulting  product
  sales.
  
  Chiroscience  has  an  extensive patent position with  PDE4  inhibitors.  18
  patent applications have been filed and 6 granted to date.
  
  Dr John Padfield, Chief Executive Officer of Chiroscience commented:
  
  "Chiroscience  has  always believed that it had sound understanding  of  the
  role  PDE4  plays in inflammatory disease and, in particular, how  selective
  drugs  can  be  designed to optimise the therapeutic window.  Chiroscience's
  knowledge  in  this  field is covered by an extensive  patent  estate,  thus
  providing   a   strong  intellectual  property  position.   The  development
  milestone  that  we  have achieved marks an important step  forward  in  our
  collaboration with Schering-Plough."
  
  For further information contact:
  Dr John Padfield, Chief Executive        Giles Sanderson/Victoria
  Christine Soden, Finance Director        Springett
  David Dible, Head of Media and           Financial Dynamics
  Investor Relations                       Tel: +44 (0)171 831 3113
  Chiroscience Group plc
  Tel: +44 (0)1223 420430                  
  Http://www.chiroscience.com
 
END 


MSCALLITSLITFAA

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024